IDEAS home Printed from https://ideas.repec.org/a/spr/aphecp/v19y2021i1d10.1007_s40258-020-00586-5.html
   My bibliography  Save this article

Effect of an Online Reimbursement Application System on Prescribing of Lidocaine 5% Medicated Plaster in the Republic of Ireland

Author

Listed:
  • Amelia Smith

    (Trinity College Dublin, Trinity Centre for Health Sciences, St. James’ Hospital
    St. James’ Hospital)

  • Stephen Doran

    (Trinity College Dublin, Trinity Centre for Health Sciences, St. James’ Hospital
    St. James’ Hospital)

  • Maria Daly

    (Trinity College Dublin, Trinity Centre for Health Sciences, St. James’ Hospital
    St. James’ Hospital)

  • Cormac Kennedy

    (Trinity College Dublin, Trinity Centre for Health Sciences, St. James’ Hospital)

  • Michael Barry

    (Trinity College Dublin, Trinity Centre for Health Sciences, St. James’ Hospital
    St. James’ Hospital)

Abstract

Background The lidocaine 5% medicated plaster, Versatis®, has one therapeutic indication listed on the Summary of Product Characteristics—symptomatic relief of post-herpetic neuralgia (PHN) in adults. Increased expenditure on Versatis® suggests that there is considerable off-label use. To support the appropriate use of Versatis®, the Health Service Executive’s Primary Care Reimbursement Service (PCRS) introduced a reimbursement application system for Versatis® from 1 September 2017. Objective The aim of this study was to investigate the effect of introducing a reimbursement application system on Versatis® prescribing under the General Medical Services (GMS) scheme. Methods This study was carried out using prescription dispensing data from the PCRS pharmacy claims database. We carried out segmented linear regression to assess changes in the Versatis® prescribing rate per 1000 GMS eligible population, before and after the introduction of the online reimbursement application system. Results The results of the segmented regression analysis show that there was a statistically significant level (− 4.91, p

Suggested Citation

  • Amelia Smith & Stephen Doran & Maria Daly & Cormac Kennedy & Michael Barry, 2021. "Effect of an Online Reimbursement Application System on Prescribing of Lidocaine 5% Medicated Plaster in the Republic of Ireland," Applied Health Economics and Health Policy, Springer, vol. 19(1), pages 133-140, January.
    • Handle: RePEc:spr:aphecp:v:19:y:2021:i:1:d:10.1007_s40258-020-00586-5
    DOI: 10.1007/s40258-020-00586-5
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40258-020-00586-5
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s40258-020-00586-5?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Aaron S Kesselheim & Jessica A Myers & Daniel H Solomon & Wolfgang C Winkelmayer & Raisa Levin & Jerry Avorn, 2012. "The Prevalence and Cost of Unapproved Uses of Top-Selling Orphan Drugs," PLOS ONE, Public Library of Science, vol. 7(2), pages 1-7, February.
    Full references (including those not matched with items on IDEAS)

    Citations

    Blog mentions

    As found by EconAcademics.org, the blog aggregator for Economics research:
    1. Chris Sampson’s journal round-up for 1st February 2021
      by Chris Sampson in The Academic Health Economists' Blog on 2021-02-01 12:00:03

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Dyfrig A Hughes & Jannine Poletti-Hughes, 2016. "Profitability and Market Value of Orphan Drug Companies: A Retrospective, Propensity-Matched Case-Control Study," PLOS ONE, Public Library of Science, vol. 11(10), pages 1-12, October.
    2. Caridad Pontes & Corinne Zara & Josep Torrent-Farnell & Merce Obach & Cristina Nadal & Patricia Vella-Bonanno & Michael Ermisch & Steven Simoens & Renata Curi Hauegen & Jolanta Gulbinovic & Angela Tim, 2020. "Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of Olaratumab," Applied Health Economics and Health Policy, Springer, vol. 18(1), pages 5-16, February.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:aphecp:v:19:y:2021:i:1:d:10.1007_s40258-020-00586-5. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.